Restoring p53-mediated apoptosis in cancer cells: New opportunities for cancer therapy

被引:72
作者
Yu, Qiang [1 ]
机构
[1] Gen Inst Singapore, Mol Pharmacol Lab, Singapore 138672, Singapore
关键词
p53; apoptosis; transcription; mitochondria : cancer therapeutic : drug discovery;
D O I
10.1016/j.drup.2006.03.001
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The p53 gene is the most commonly mutated gene known in human tumors: over half of human tumors contain inactivating mutations in p53. In the past decade, the role of p53 as apoptotic trigger has been well demonstrated both in vitro and in vivo. Many chemotherapeutic agents cause DNA damage and activate the p53 pathway to induce growth arrest and apoptosis. However. the p53 function is often inactivated or suppressed in human cancers. Thus. functional restoration of this pathway is an attractive therapeutic strategy. In recent years. a number of therapeutic approaches aiming at modulation of the p53 pathway have been developed and will be reviewed here. The focus will be on recent developments elucidating a transcription-independent mechanism of p53-mediated apoptosis and the therapeutic opportunities arising from this new mechanism. (c) 2006 Elsevier Ltd. All rights reserved.
引用
收藏
页码:19 / 25
页数:7
相关论文
共 74 条
[1]   Effect of mutated TP53 on response of advanced breast cancers to high-dose chemotherapy [J].
Bertheau, P ;
Plassa, F ;
Espié, M ;
Turpin, E ;
de Roquancourt, A ;
Marty, M ;
Lerebours, F ;
Beuzard, Y ;
Janin, A ;
de Thé, H .
LANCET, 2002, 360 (9336) :852-854
[2]   The mTOR inhibitor RAD001 sensitizes tumor cells to DNA-damaged induced apoptosis through inhibition of p21 translation [J].
Beuvink, I ;
Boulay, A ;
Fumagalli, S ;
Zilbermann, F ;
Ruetz, S ;
O'Reilly, T ;
Natt, F ;
Hall, J ;
Lane, HA ;
Thomas, G .
CELL, 2005, 120 (06) :747-759
[3]   Disruption of p53 in human cancer cells alters the responses to therapeutic agents [J].
Bunz, F ;
Hwang, PM ;
Torrance, C ;
Waldman, T ;
Zhang, YG ;
Dillehay, L ;
Williams, J ;
Lengauer, C ;
Kinzler, KW ;
Vogelstein, B .
JOURNAL OF CLINICAL INVESTIGATION, 1999, 104 (03) :263-269
[4]  
Bunz F, 2002, CANCER RES, V62, P1129
[5]   Small molecules that reactivate mutant p53 [J].
Bykov, VJN ;
Selivanova, G ;
Wiman, KG .
EUROPEAN JOURNAL OF CANCER, 2003, 39 (13) :1828-1834
[6]   Mutant p53-dependent growth suppression distinguishes PRIMA-1 from known anticancer drugs: a statistical analysis of information in the National Cancer Institute database [J].
Bykov, VJN ;
Issaeva, N ;
Selivanova, G ;
Wiman, KG .
CARCINOGENESIS, 2002, 23 (12) :2011-2018
[7]   Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound [J].
Bykov, VJN ;
Issaeva, N ;
Shilov, A ;
Hultcrantz, M ;
Pugacheva, E ;
Chumakov, P ;
Bergman, J ;
Wiman, KG ;
Selivanova, G .
NATURE MEDICINE, 2002, 8 (03) :282-288
[8]   P53-DEPENDENT APOPTOSIS IN THE ABSENCE OF TRANSCRIPTIONAL ACTIVATION OF P53-TARGET GENES [J].
CAELLES, C ;
HELMBERG, A ;
KARIN, M .
NATURE, 1994, 370 (6486) :220-223
[9]   Activation of p53 by MDM2 antagonists can protect proliferating cells from mitotic inhibitors [J].
Carvajal, D ;
Tovar, C ;
Yang, H ;
Vu, BT ;
Heimbrook, DC ;
Vassilev, LT .
CANCER RESEARCH, 2005, 65 (05) :1918-1924
[10]   Pharmacologic activation of p53 elicits Bax-dependent apoptosis in the absence of transcription [J].
Chipuk, JE ;
Maurer, U ;
Green, DR ;
Schuler, M .
CANCER CELL, 2003, 4 (05) :371-381